EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Embedding Patient Input in Outcome Measures for Long‐Term Disease‐Modifying Parkinson Disease Trials

Cristina Gonzalez-Robles iD, Michèle Bartlett, Matthew Burnell, Caroline S Clarke, Shlomi Haar, Michele T Hu iD, Brook Huxford iD, Ashwani Jha iD, Michael Lawton, Alastair Noyce iD, Paola Piccini, Kuhan Pushparatnam und 11 weitere

Movement Disorders · 2024-02 · 39 (2) · 433-438

DOI: 10.1002/mds.29691 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 22.12.2023. Verfasst von Cristina Gonzalez-Robles und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wellcome Trust, Edmond J Safra Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical trials of disease‐modifying therapies in PD require valid and responsive primary outcome measures that are relevant to patients.

Objectives

The objective is to select a patient‐centered primary outcome measure for disease‐modification trials over three or more years.

Methods

Experts in Parkinson's disease (PD), statistics, and health economics and patient and public involvement and engagement (PPIE) representatives reviewed and discussed potential outcome measures. A larger PPIE group provided input on their key considerations for such an endpoint. Feasibility, clinimetric properties, and relevance to patients were assessed and synthesized.

Results

Although initial considerations favored the Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS) Part III in Off, feasibility, PPIE input, and clinimetric properties supported the MDS‐UPDRS Part II. However, PPIE input also highlighted the importance of nonmotor symptoms, especially in the longer term, leading to the selection of the MDS‐UPDRS Parts I + II sum score.

Conclusions

The MDS‐UPDRS Parts I + II sum score was chosen as the primary outcome for large 3‐year disease‐modification trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseHumansSeverity of Illness IndexMental Status and Dementia TestsSocieties, Medical

Stichwörter der Autor:innen

Parkinson diseasePatient and Public Involvement and Engagament (PPIE)clinical trialsdisease modificationendpointsoutcome measures

Autor:innen und Institutionen

  • Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
  • Expert by experience, Guildford, United Kingdom.
  • Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom.
  • Department of Brain Sciences, Imperial College London, London, United Kingdom.
  • Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
  • Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom.

ORCID-Profile: Cristina Gonzalez-Robles, Michele T Hu, Brook Huxford, Ashwani Jha, Alastair Noyce, Daniel van Wamelen, Caroline H Williams-Gray, Thomas Foltynie, Rimona S Weil, Anette Schrag

Förderung

  • Wellcome Trust
  • Edmond J Safra Foundation

Zitieren

APA

Gonzalez-Robles, C., Bartlett, M., Burnell, M., Clarke, C. S., Haar, S., Hu, M. T., Huxford, B., Jha, A., Lawton, M., Noyce, A., Piccini, P., Pushparatnam, K., Rochester, L., Siu, C., van Wamelen, D., Williams-Gray, C. H., Zeissler, M. L., Zetterberg, H., Carroll, C. B., …, & EJS ACT-PD Consortium (2024). Embedding Patient Input in Outcome Measures for Long‐Term Disease‐Modifying Parkinson Disease Trials. Movement Disorders, 39(2), 433-438. https://doi.org/10.1002/mds.29691

Vancouver

Gonzalez-Robles C, Bartlett M, Burnell M, Clarke CS, Haar S, Hu MT, et al. Embedding Patient Input in Outcome Measures for Long‐Term Disease‐Modifying Parkinson Disease Trials. Movement Disorders. 2024;39(2):433-438. doi:10.1002/mds.29691

BibTeX
@article{GonzalezRobles2024,
  author = {Gonzalez-Robles, Cristina and Bartlett, Michèle and Burnell, Matthew and Clarke, Caroline S and Haar, Shlomi and Hu, Michele T and Huxford, Brook and Jha, Ashwani and Lawton, Michael and Noyce, Alastair and Piccini, Paola and Pushparatnam, Kuhan and Rochester, Lynn and Siu, Carroll and van Wamelen, Daniel and Williams-Gray, Caroline H and Zeissler, Marie-Louise and Zetterberg, Henrik and Carroll, Camille B and Foltynie, Thomas and Weil, Rimona S and Schrag, Anette and EJS ACT-PD Consortium, EJS ACT-PD Consortium},
  title = {Embedding Patient Input in Outcome Measures for Long‐Term Disease‐Modifying Parkinson Disease Trials},
  journal = {Movement Disorders},
  year = {2024},
  volume = {39},
  number = {2},
  pages = {433--438},
  doi = {10.1002/mds.29691}
}
Kostenlos starten →